FDA Approves MagVenture’s TMS For 3-Minute Depression-Treatment Sessions

On August 23, 2018, the U.S. Food and Drug Administration (FDA) approved MagVenture's MagVita Transcranial Magnetic Stimulation System (TMS) for use in three-minute sessions to treat severe depression. MagVenture, a Danish company, specializes in non-invasive repetitive TMS devices for the treatment of major depressive disorder. Currently, this device has FDA clearance for the treatment of severe depression in 19- to 38-minute treatments using 3,000 pulses of 10 hertz (Hz) stimulation. However, the new 600-pulses protocol uses intermittent theta-burst stimulation (iTBS), a newer form of TMS that can be delivered in three minutes . . .